Previous 10 | Next 10 |
Opiant Pharmaceuticals press release (NASDAQ:OPNT): Q4 GAAP EPS of $0.11 beats by $0.01. Revenue of $13.8M (+39.1% Y/Y) beats by $0.54M. For further details see: Opiant Pharmaceuticals GAAP EPS of $0.11 beats by $0.01, revenue of $13.8M beats by $0.54M
Opiant Pharmaceuticals (NASDAQ:OPNT) is scheduled to announce Q4 earnings results on Tuesday, Mar. 15, after market close. The consensus EPS estimate is $0.10 and the consensus revenue estimate is $13.26M (+32.6% Y/Y). Over the last 2 years, OPNT has beaten EPS estimates 75% of the...
OTCPK:ANCUF, ATHX, CAL, CHMI, CLPR, FF, GOCO, HYRE, KODK, LFT, LOTZ, LX, MTN, OPNT, S, SFT, SMAR, SRG, SRGA, TCON, YALA, YY, ZDGE For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings after Tuesday's close
SANTA MONICA, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr. Roger Crystal, ...
SANTA MONICA, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 2021 financial res...
SANTA MONICA, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a multi-dose pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, an investigational treatment ...
Opiant Pharmaceuticals (NASDAQ:OPNT) briefly gained 1.5% after a report that the company is speculated to be a takeover target. A large rival is said to be circling the pharmaceutical company, according to a Betaville "uncooked" alert. Opiant (OPNT) didn't respond to Betaville reque...
SANTA MONICA, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an additiona...
SANTA MONICA, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation Commi...
Shares of Opiant Pharmaceuticals Inc. (NASDAQ:OPNT) traded today at $29.02, eclipsing its 52-week high. So far today approximately 949,000 shares have been exchanged, as compared to an average 30-day volume of 49,000 shares. Opiant Pharmaceuticals Inc is a specialty pharmaceutical compan...
News, Short Squeeze, Breakout and More Instantly...
Opiant Pharmaceuticals Inc. Company Name:
OPNT Stock Symbol:
NASDAQ Market:
CFIUS clearance represents the final required regulatory approval to complete the proposed merger Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023 Indivior and Opiant c...
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant...
FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for...